SIERRA ONCOLOGY
DEAD

Serial Number

90848313

Owner

Sierra Oncology, Inc.

Attorney

Christopher M. Hanes

Filing Date

Jul 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SIERRA ONCOLOGY Trademark

Serial Number: 90848313

SIERRA ONCOLOGY is a trademark filed by Sierra Oncology, Inc. on July 26, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Sierra Oncology, Inc. (8 trademarks)

Corporation Service Company
Wilmington, DE 19808

Entity Type: 03

SIERRA ONCOLOGY LLC

CORPORATION SERVICE COMPANY
WILMINGTON, DE 19808

Entity Type: 16

Trademark Details

Filing Date

July 26, 2021

Registration Date

Not Registered

Published for Opposition

December 6, 2022

Goods & Services

Biological and chemical preparations for the treatment of cancer; pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and disorders; pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation; pharmaceutical preparations for use in the prevention and treatment of dermatology, oncology, hematology and for gastroenterological disorders but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation

Medical services; medical services for the treatment of cancer; medical analysis services for the diagnosis and treatment of patients and persons; medical analysis services for the diagnosis of cancer; providing cancer screening services; providing a website via a global computer network featuring information in the fields of health and health information regarding cancer, cancer treatment, recovery and survival; medical evaluation and diagnosis of cancer; medical analysis for cancer diagnosis and prognosis based on DNA and RNA screening; medical services for the diagnosis of conditions of the human body; providing a website via a global computer network featuring information regarding the medical diagnosis and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing a website via a global computer network featuring information regarding the medical diagnosis and treatment of dermatology, oncology, hematology, and for gastroenterological disorders; providing medical information, consultancy and advisory services; providing links to the websites of others featuring information about the diagnosis and treatment of cancer

Development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines; medical research; pharmaceutical research and development services; medical research services in the field of cancer; research and development of biological and chemical preparations for the treatment of blood diseases, bone and bone marrow diseases, and cancer; research and development of pharmaceutical products, preparations and compounds for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development of pharmaceutical preparations for use in dermatology, oncology, hematology, and for gastroenterological disorders; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials regarding pharmaceutical preparations and drugs in the field of blood diseases, and cancers; DNA screening and analysis services for scientific research purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 4, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 4, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 2, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jul 31, 2023 EX1G
SOU EXTENSION 1 FILED
Jul 31, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 31, 2023 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 8, 2023 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 31, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 6, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 6, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 16, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 31, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 20, 2022 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 12, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 12, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 12, 2022 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 21, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 21, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 21, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 20, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 24, 2021 NWOS
NEW APPLICATION ENTERED
Jul 29, 2021 NWAP